BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30803874)

  • 1. Management and surveillance of non-functional pancreatic neuroendocrine tumours: Retrospective review.
    Yohanathan L; Dossa F; St Germain AT; Golbafian F; Moulton CA; McGilvray ID; Greig PD; Serra S; Wei AC; Jhaveri KS; Gallinger S; Cleary SP
    Pancreatology; 2019 Mar; 19(2):360-366. PubMed ID: 30803874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis.
    Kurita Y; Hara K; Kuwahara T; Mizuno N; Okuno N; Haba S; Okuno M; Natsume S; Senda Y; Kubota K; Nakajima A; Niwa Y; Shimizu Y
    J Gastroenterol; 2020 May; 55(5):543-552. PubMed ID: 31858231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.
    Qiu W; Christakis I; Silva A; Bassett RL; Cao L; Meng QH; Gardner Grubbs E; Zhao H; Yao JC; Lee JE; Perrier ND
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):400-7. PubMed ID: 27256431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.
    Partelli S; Cirocchi R; Crippa S; Cardinali L; Fendrich V; Bartsch DK; Falconi M
    Br J Surg; 2017 Jan; 104(1):34-41. PubMed ID: 27706803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors.
    Gaujoux S; Partelli S; Maire F; D'Onofrio M; Larroque B; Tamburrino D; Sauvanet A; Falconi M; Ruszniewski P
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4784-9. PubMed ID: 24057286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endosonographic and cyst fluid characteristics of cystic pancreatic neuroendocrine tumours: a multicentre case series.
    Ho HC; Eloubeidi MA; Siddiqui UD; Brugge WR; Rossi F; Bounds BW; Aslanian HR
    Dig Liver Dis; 2013 Sep; 45(9):750-3. PubMed ID: 23582348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonfunctioning, small, incidental pancreatic neuroendocrine tumors: Results of a nonoperative approach cohort.
    Uribe Galeano C; Fabregat Prous J; Busquets Barenys J; Pelaez Serra N; Secanella Medayo L; Ramos Rubio E; Ruiz Osuna S; Villabona Artero C
    Cir Esp; 2017 Feb; 95(2):83-88. PubMed ID: 28162264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality.
    Wu J; Sun C; Li E; Wang J; He X; Yuan R; Yi C; Liao W; Wu L
    BMC Cancer; 2019 Apr; 19(1):334. PubMed ID: 30961556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.
    Lee LC; Grant CS; Salomao DR; Fletcher JG; Takahashi N; Fidler JL; Levy MJ; Huebner M
    Surgery; 2012 Dec; 152(6):965-74. PubMed ID: 23102679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis.
    Sallinen V; Le Large TY; Galeev S; Kovalenko Z; Tieftrunk E; Araujo R; Ceyhan GO; Gaujoux S
    HPB (Oxford); 2017 Apr; 19(4):310-320. PubMed ID: 28254159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.
    Sadot E; Reidy-Lagunes DL; Tang LH; Do RK; Gonen M; D'Angelica MI; DeMatteo RP; Kingham TP; Groot Koerkamp B; Untch BR; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2016 Apr; 23(4):1361-70. PubMed ID: 26597365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?
    Qiu W; Christakis I; Stewart AA; Vodopivec DM; Silva-Figueroa A; Chen H; Woodard TL; Halperin DM; Lee JE; Yao JC; Perrier ND
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):791-797. PubMed ID: 28273369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
    Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
    Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.
    Nikou GC; Marinou K; Thomakos P; Papageorgiou D; Sanzanidis V; Nikolaou P; Kosmidis C; Moulakakis A; Mallas E
    Pancreatology; 2008; 8(4-5):510-9. PubMed ID: 18765956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours.
    Reher D; Fehrenbach U; Kayser A; Pape UF; Henes FO; Cremer B; Hörsch D; Izbicki J; Lohse AW; Rinke A; Schrader J
    Neuroendocrinology; 2022; 112(6):595-605. PubMed ID: 34515157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical treatment of pancreatic neuroendocrine tumours - clinical experience.
    Jabłońska B; Dranka-Bojarowska D; Palacz H; Lewiński A; Lampe P
    Pol Przegl Chir; 2011 Apr; 83(4):216-22. PubMed ID: 22166361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A "Watch and Wait" Strategy Involving Regular Endoscopic Surveillance Is Safe for Many Patients with Small, Sporadic, Grade 1, Non-Ampullary, Non-Functioning Duodenal Neuroendocrine Tumours.
    Exarchou K; Moore AR; Smart HL; Duckworth CA; Howes N; Pritchard DM
    Neuroendocrinology; 2021; 111(8):764-774. PubMed ID: 32937631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
    Jann H; Denecke T; Koch M; Pape UF; Wiedenmann B; Pavel M
    Neuroendocrinology; 2013; 98(2):137-43. PubMed ID: 23797176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
    de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
    Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of pancreatic neuroendocrine tumors.
    Dickson PV; Behrman SW
    Surg Clin North Am; 2013 Jun; 93(3):675-91. PubMed ID: 23632152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.